




























PHASES OF CF CLINICAL RESEARCH

Phase	Length	Number of People*		Purpose	
Phase 1	 1 month	 10-20	 Is it safe?	 How does the body process it?	 What are the side effects?
Phase 2	 3 - 12 months	 50-75	 Is it safe?	 How well is it working?	 How much should be taken?
Phase 3	 6 - 12 months	 100-300	 Is it safe?	 How well is it working?	 Does the benefit outweigh the risk?
<div> <div>If successful</div> <div>FDA Approval</div> <div>  Application submitted   Application reviewed   Application approved   Available to public </div> <div>(6-12 months)</div> </div>					
Phase 4	 3 - 12 months	 100-300	 Does it still appear to be safe?	 Are there rare side effects?	 Cost effectiveness & comparison to other similar drugs

 = 15 healthy participants

 = 15 participants with CF

 = Number of months of participant involvement

*number of participants varies based on study characteristics